Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma
Adoptive cellular immunotherapy with anti CD19 chimeric antigen receptor (CAR)-T cell has changed the treatment landscape in relapsed/refractory B cell lymphomas. They have emerged as effective therapy in patients with multiple relapsed/refractory disease, capable of sustaining durable remissions. Two CAR-T cell products (axicabtagene ciloleucel and tisagenlecleucel) are currently approved by the United States Food and Drug Administration. A third anti CD19 CAR-T cell, lisocabtagene ciloleucel is currently being evaluated in large clinical trials and may also be United States Food and Drug Administration-approved soon.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Avyakta Kallam, Julie M. Vose Tags: Review Source Type: research
More News: Clinical Trials | Food and Drug Administration (FDA) | Hematology | Hodgkin's Disease | Immunotherapy | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | USA Health